Based on long-term follow-up data, the survival rates for CAR-T cell therapy patients vary depending on the specific cancer type and study, but generally show promising results:
-
For patients with large B-cell lymphoma:
• The estimated overall survival rate at 12 months was 59.4%.
• In the ZUMA-1 trial, 52% of patients were alive at 18 months. -
For patients with chronic lymphocytic leukemia (CLL):
• The five-year overall survival rate was 78.6% with monotherapy and 70.6% with combination therapy. -
For pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL):
• The median survival was 19.1 months in the ELIANA trial. -
For adult patients with relapsed B-ALL:
• The median survival was 12.9 months in a study by Memorial Sloan Kettering Cancer Center. -
For patients with diffuse large B-cell lymphoma (DLBCL):
• The median survival was 22.2 months in the JULIET trial.
It's important to note that while some patients experience long-term remission lasting over a decade, more than half may relapse within 12 months. However, research is ongoing to improve long-term outcomes, with some studies showing that 35-40% of patients achieve 5-year remission in real-world data.
Sources:
ashpublications.org
targetedonc.com
webmd.com
lymphoma.org
pubmed
pmc.ncbi.nlm.nih.gov
onclive.com
nature.com
Publication date: March 2025
